AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04049175
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of CHF 6532
Trial: NCT01508468
Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
Trial: NCT01508468
Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
Trial: NCT01512160
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x 200 mg tablets
Trial: NCT01912261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule orally daily times 84 days
Trial: NCT01912261
Drug: Polysaccharide iron complex
RxNorm normalized name: polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg daily orally times 84 days
Trial: NCT00408213
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g po bid
Trial: NCT00408213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po bid
Trial: NCT01108627
Drug: open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
Trial: NCT01108627
Drug: foradil placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: open-labeled inhaled corticosteroids (ICS); foradil placebo
Trial: NCT02535273
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
Trial: NCT02477293
Drug: Hyeonggaeyeongyo-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03945188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Trial: NCT01515410
Drug: Sinemet IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
Trial: NCT02219048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 680 micrograms BID, Orally inhaled placebo for 12 weeks
Trial: NCT04794803
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT04149405
Drug: Bisphosphonate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
Trial: NCT01250977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
Trial: NCT02871648
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epleronone 100 mg
Trial: NCT00439868
Drug: WellbutrinXL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
Trial: NCT00439868
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets to WELLBUTRIN XL.
Trial: NCT01590303
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
Trial: NCT01884038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01587508
Drug: meloxicam/cyclobenzaprine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two oral capsules a day during approximately 07 days
Trial: NCT01587508
Drug: meloxicam - Movatec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two oral tablet a day during approximately 07 days
Trial: NCT00191607
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02729909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone placebo-matching capsules
Trial: NCT00559533
Drug: RO5045337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
Trial: NCT01971047
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose
Trial: NCT02660905
Drug: E/C/F/TAF;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Trial: NCT01358747
Drug: BEACOPPesc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04052620
Drug: Diclofenac diethylamine 2.32% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Trial: NCT04052620
Drug: Diclofenac diethylamine 1.16% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
Trial: NCT01321827
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
Trial: NCT00329082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5: Placebo QW IV for 12 weeks
Trial: NCT00922740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Trial: NCT03657225
Drug: Utilization of the conventional circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of the mini CPB circuit to conventional circuit
Trial: NCT00153972
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02215967
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Trial: NCT03959969
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
Trial: NCT00168779
Drug: telmisartan 80 mg / hydrochlorothiazide 25 mg
RxNorm normalized name: TELMISARTAN 80 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168779
Drug: valsartan 160 mg / hydrochlorothiazide 25 mg
RxNorm normalized name: valsartan 160 MG / hydroCHLOROthiazide 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168779
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03447743
Drug: XR-NTX community location
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX will be administered at the local health care clinic
Trial: NCT02046603
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
Trial: NCT02046603
Drug: Oral Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
Trial: NCT02046603
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate per investigator's discretion.
Trial: NCT00325247
Drug: ZINC
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02461160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching TAK-915 suspension
Trial: NCT02854527
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose
Trial: NCT02854527
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
Trial: NCT02390882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02390882
Drug: HIP1402 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulon high dose
Trial: NCT02065076
Drug: Lactose with carob gum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01480245
Drug: GSK2402968
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg/kg/week
Trial: NCT02367976
Drug: rhprouk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
Trial: NCT01370031
Drug: Clenil® Modulite® via Volumatic™ spacer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
Trial: NCT01370031
Drug: Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
Trial: NCT02157324
Drug: ACP-319
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02315131
Drug: TV46017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
Trial: NCT02315131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00006038
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006038
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00473590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00295997
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00295997
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06768619
Drug: Group 2: single-dose of reference formulation+single-dose of test formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
Trial: NCT01625091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
Trial: NCT00445146
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
Trial: NCT00445146
Drug: ARV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
Trial: NCT02552901
Drug: 0.1 mg/kg ICG Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: least efficacious dose
Trial: NCT02552901
Drug: 0.5 mg/kg ICG dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per package insert
Trial: NCT00619723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient matching the active medication in appearance.
Trial: NCT03893630
Drug: Acetylsalicylic Acid 81 mg
RxNorm normalized name: 5-BROMO-2-ACETYLSALICYLIC ACID 81 mg ORAL TABLET, COATED [Cardioaspirina Tabletas con cubierta enterica]
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Trial: NCT03893630
Drug: Acetylsalicylic Acid 162 mg
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Trial: NCT02390947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg p.o. qd
Trial: NCT02579252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03857646
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
Trial: NCT03888066
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Trial: NCT03786029
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Trial: NCT01860235
Drug: Injectable anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
Trial: NCT01860235
Drug: 2% Benzocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthetic - 200mg/g of 2% benzocaine
Trial: NCT01860235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
Trial: NCT03786029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Trial: NCT03786029
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Trial: NCT00030719
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03422874
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
Trial: NCT04393441
Drug: 011516X (New Artificial Tear Formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eye drops
Trial: NCT04393441
Drug: Systane Ultra Multidose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eye drops
Trial: NCT04393441
Drug: REFRESH PLUS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eye drops
Trial: NCT03756103
Drug: SPH3127 tablet Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
Trial: NCT03756103
Drug: SPH3127 tablet Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
Trial: NCT03756103
Drug: SPH3127 tablet Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
Trial: NCT01838850
Drug: CS8635 20/5/12.5mg and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day.
Trial: NCT02371655
Drug: Faecal Tagging
RxNorm normalized name: Enterococcus faecalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
Trial: NCT02371655
Drug: Bowel cleansing
RxNorm normalized name: Dulcolax Bowel Cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
Trial: NCT03756103
Drug: SPH3127 tablet Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPH3127 tablet placebo, once daily for 8 weeks.
Trial: NCT03516448
Drug: Gan Fu Le Tablets
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 Tablets，tid,po
Trial: NCT03516448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg/d, 5days,ivgtt